

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



PROFIT WARNING SUPPLEMENTAL ANNOUNCEMENT

This announcement is made by China NT Pharma Group Company Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Reference is made to the announcement of the Company dated 31 July 2020 (the “**Announcement**”) in relation to the profit warning of the Company for the Period Under Review. Unless otherwise defined, capitalised terms used herein shall have the same meanings as defined in the Announcement.

The Board wishes to provide further information to the Shareholders and potential investors of the Company that, based on the information currently available to the Group, the Group is expected to record a net loss of approximately RMB85.0 million for the Period Under Review, as compared to a net profit of RMB3.7 million recorded for the corresponding period in 2019.

This announcement is made solely based on the preliminary assessment of the Board after reviewing the estimated financial results of the Group and the information currently available to the Group, which is still in the process of being finalized and which has not been reviewed by the Company’s auditors. Further details of the Company’s financial performance will be provided in the announcement for the interim results of the Group for the Period Under Review, which is expected to be published before the end of August 2020.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By Order of the Board
China NT Pharma Group Company Limited
Ng Tit
Chairman

Hong Kong, 6 August 2020

As at the date of this announcement, the executive Directors are Mr. Ng Tit, Ms. Chin Yu and Mr. Wu Weizhong; the non-executive Director is Dr. Qian Wei; and the independent non-executive Directors are Mr. Tze Shan Hailson Yu, Mr. Pan Fei and Dr. Zhao Yubiao.